Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Feb 21, 2019 9:45am

88 Views

Post# 29393136

RE:RE:RE:RE:RE:RE:NASH results at the end of March early April

So early April hopefully (still Grinspoon has control over this). Coincides with next cc but also the EASL 2019 conference which is where Intercept present their data. Shame it wont be presented there but still the buzz around NASH should be high.

SPCEO1 wrote: That was very encouraging - I hope the analysts were paying attention. It will be interesting to see what they say about NASH. And we now know the time frame for when to expect the results.

Wino115 wrote: I did like the "immediately look for ways to commercialize" and that it could "rapidly have impact". Pretty clear that they have thought about this in depth given how detailed their response was about the FDA, testing, label, how they may go about it. Was very good sign for the HIV NASH market part.